CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other cancer indications Avidicure is developing dual agonistic, multifunctional and ...

At this year’s ABRF Annual Meeting (23–26 March; NV, USA), biotech companies had the opportunity to showcase their technology, highlighting how their products are facilitating breakthroughs in the ...

Component Supply will distribute Resenex’s proprietary medical check valves, connectors, caps, and other fluid management ...

In this article, we will be taking a look at the 7 most profitable biotech stocks to buy right ... learning for precision oncology and protein design. The RNA therapeutics sector is also booming ...

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

The Trump administration’s deep rollbacks on medical research funding are eroding a key pillar of the American biotechnology ... a professor of engineering design at Pennsylvania State ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

Or how to assess a biotech company's drug product pipeline ... we plan to meet with the FDA regarding the design of what we expect will be a single 24-week treatment duration Phase 3 clinical ...